Quinn Opportunity Partners LLC Invests $56,000 in Repare Therapeutics Inc. $RPTX

Quinn Opportunity Partners LLC acquired a new position in Repare Therapeutics Inc. (NASDAQ:RPTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 40,000 shares of the company’s stock, valued at approximately $56,000. Quinn Opportunity Partners LLC owned approximately 0.09% of Repare Therapeutics at the end of the most recent reporting period.

Separately, Affinity Asset Advisors LLC boosted its holdings in Repare Therapeutics by 100.0% in the first quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock worth $197,000 after acquiring an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on RPTX. HC Wainwright cut their price objective on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, October 27th. Wall Street Zen raised shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $3.50.

Repare Therapeutics Stock Performance

Shares of RPTX opened at $1.72 on Thursday. The business’s 50-day moving average is $1.78 and its two-hundred day moving average is $1.58. The company has a market capitalization of $73.89 million, a P/E ratio of -0.67 and a beta of 1.06. Repare Therapeutics Inc. has a fifty-two week low of $0.89 and a fifty-two week high of $4.07.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.